First patient dosed in pivotal Phase 3 trial for novel antifungal for both treatment and prevention of serious fungal infections
by Press Release from Outbreak News Today on (#53W6D)
Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal candidate, rezafungin, for the [...]
The post First patient dosed in pivotal Phase 3 trial for novel antifungal for both treatment and prevention of serious fungal infections appeared first on Outbreak News Today.